 | • レポートコード：MRC2312MG13024 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場規模と予測を収録しています。・世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場：売上、2018年-2023年、2024年-2029年 ・世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「直接阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 キルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤のグローバル主要企業は、Amgen、 Mirati Therapeutics、 Novartis、 Genentech、 Verastem Oncology、 Revolution Medicines、 Cardiff Oncology、 Immuneering Corporation、 Jacobio Pharmaceuticals、 BridgeBio Pharma、 Deciphera Pharmaceuticals、 Elicio Therapeutics、 InventisBio、 Gritstone Bio、 D3 Bioなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、キルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場：タイプ別、2018年-2023年、2024年-2029年 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場：タイプ別市場シェア、2022年 ・直接阻害剤、シグナル伝達阻害剤 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場：用途別、2018年-2023年、2024年-2029年 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場：用途別市場シェア、2022年 ・小売薬局、病院薬局、オンライン薬局 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場：地域・国別、2018年-2023年、2024年-2029年 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤のグローバル売上、2018年-2023年 ・主要企業におけるキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤のグローバル売上シェア、2022年 ・主要企業におけるキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤のグローバル販売量、2018年-2023年 ・主要企業におけるキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Amgen、 Mirati Therapeutics、 Novartis、 Genentech、 Verastem Oncology、 Revolution Medicines、 Cardiff Oncology、 Immuneering Corporation、 Jacobio Pharmaceuticals、 BridgeBio Pharma、 Deciphera Pharmaceuticals、 Elicio Therapeutics、 InventisBio、 Gritstone Bio、 D3 Bio ************************************************************* ・調査・分析レポートの概要 キルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場の定義 市場セグメント 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場規模 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場規模：2022年 VS 2029年 世界のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のキルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：直接阻害剤、シグナル伝達阻害剤 キルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：小売薬局、病院薬局、オンライン薬局 キルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤の用途別グローバル売上・予測 ・地域別市場分析 地域別キルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤市場規模 2022年と2029年 地域別キルステンラット肉腫ウイルス癌遺伝子ホモログ（KRAS）阻害剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Amgen、 Mirati Therapeutics、 Novartis、 Genentech、 Verastem Oncology、 Revolution Medicines、 Cardiff Oncology、 Immuneering Corporation、 Jacobio Pharmaceuticals、 BridgeBio Pharma、 Deciphera Pharmaceuticals、 Elicio Therapeutics、 InventisBio、 Gritstone Bio、 D3 Bio ... |
This research report provides a comprehensive analysis of the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, challenges faced by the industry, and potential opportunities for market players.
The global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market presents opportunities for various stakeholders, including Retail Pharmacy, Hospital Pharmacy. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market. Additionally, the growing consumer demand present avenues for market expansion.
The global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market.
Market Overview: The report provides a comprehensive overview of the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Direct Inhibitors, Signal transduction inhibitors), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Direct Inhibitors
Signal transduction inhibitors
Market segment by Application
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Amgen
Mirati Therapeutics
Novartis
Genentech
Verastem Oncology
Revolution Medicines
Cardiff Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
BridgeBio Pharma
Deciphera Pharmaceuticals
Elicio Therapeutics
InventisBio
Gritstone Bio
D3 Bio
Outline of Major Chapters:
Chapter 1: Introduces the definition of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, market overview.
Chapter 2: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size in revenue.
Chapter 3: Detailed analysis of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Overall Market Size
2.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size: 2022 VS 2029
2.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players in Global Market
3.2 Top Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies Ranked by Revenue
3.3 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Companies
3.4 Top 3 and Top 5 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies in Global Market, by Revenue in 2022
3.5 Global Companies Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Type
3.6 Tier 1, Tier 2 and Tier 3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players in Global Market
3.6.1 List of Global Tier 1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies
3.6.2 List of Global Tier 2 and Tier 3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Markets, 2022 & 2029
4.1.2 Direct Inhibitors
4.1.3 Signal transduction inhibitors
4.2 By Type – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue & Forecasts
4.2.1 By Type – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2018-2023
4.2.2 By Type – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2024-2029
4.2.3 By Type – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2022 & 2029
5.1.2 Retail Pharmacy
5.1.3 Hospital Pharmacy
5.1.4 Online Pharmacy
5.2 By Application – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue & Forecasts
5.2.1 By Application – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2018-2023
5.2.2 By Application – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2024-2029
5.2.3 By Application – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2022 & 2029
6.2 By Region – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue & Forecasts
6.2.1 By Region – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2018-2023
6.2.2 By Region – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2024-2029
6.2.3 By Region – Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2018-2029
6.3.2 US Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.3.3 Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.3.4 Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2018-2029
6.4.2 Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.4.3 France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.4.4 U.K. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.4.5 Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.4.6 Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.4.7 Nordic Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.4.8 Benelux Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2018-2029
6.5.2 China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.5.3 Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.5.4 South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.5.5 Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.5.6 India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2018-2029
6.6.2 Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.6.3 Argentina Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, 2018-2029
6.7.2 Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.7.3 Israel Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.7.4 Saudi Arabia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
6.7.5 UAE Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, 2018-2029
7 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies Profiles
7.1 Amgen
7.1.1 Amgen Company Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.1.4 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.1.5 Amgen Key News & Latest Developments
7.2 Mirati Therapeutics
7.2.1 Mirati Therapeutics Company Summary
7.2.2 Mirati Therapeutics Business Overview
7.2.3 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.2.4 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.2.5 Mirati Therapeutics Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.3.4 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Genentech
7.4.1 Genentech Company Summary
7.4.2 Genentech Business Overview
7.4.3 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.4.4 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.4.5 Genentech Key News & Latest Developments
7.5 Verastem Oncology
7.5.1 Verastem Oncology Company Summary
7.5.2 Verastem Oncology Business Overview
7.5.3 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.5.4 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.5.5 Verastem Oncology Key News & Latest Developments
7.6 Revolution Medicines
7.6.1 Revolution Medicines Company Summary
7.6.2 Revolution Medicines Business Overview
7.6.3 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.6.4 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.6.5 Revolution Medicines Key News & Latest Developments
7.7 Cardiff Oncology
7.7.1 Cardiff Oncology Company Summary
7.7.2 Cardiff Oncology Business Overview
7.7.3 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.7.4 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.7.5 Cardiff Oncology Key News & Latest Developments
7.8 Immuneering Corporation
7.8.1 Immuneering Corporation Company Summary
7.8.2 Immuneering Corporation Business Overview
7.8.3 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.8.4 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.8.5 Immuneering Corporation Key News & Latest Developments
7.9 Jacobio Pharmaceuticals
7.9.1 Jacobio Pharmaceuticals Company Summary
7.9.2 Jacobio Pharmaceuticals Business Overview
7.9.3 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.9.4 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.9.5 Jacobio Pharmaceuticals Key News & Latest Developments
7.10 BridgeBio Pharma
7.10.1 BridgeBio Pharma Company Summary
7.10.2 BridgeBio Pharma Business Overview
7.10.3 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.10.4 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.10.5 BridgeBio Pharma Key News & Latest Developments
7.11 Deciphera Pharmaceuticals
7.11.1 Deciphera Pharmaceuticals Company Summary
7.11.2 Deciphera Pharmaceuticals Business Overview
7.11.3 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.11.4 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.11.5 Deciphera Pharmaceuticals Key News & Latest Developments
7.12 Elicio Therapeutics
7.12.1 Elicio Therapeutics Company Summary
7.12.2 Elicio Therapeutics Business Overview
7.12.3 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.12.4 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.12.5 Elicio Therapeutics Key News & Latest Developments
7.13 InventisBio
7.13.1 InventisBio Company Summary
7.13.2 InventisBio Business Overview
7.13.3 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.13.4 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.13.5 InventisBio Key News & Latest Developments
7.14 Gritstone Bio
7.14.1 Gritstone Bio Company Summary
7.14.2 Gritstone Bio Business Overview
7.14.3 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.14.4 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.14.5 Gritstone Bio Key News & Latest Developments
7.15 D3 Bio
7.15.1 D3 Bio Company Summary
7.15.2 D3 Bio Business Overview
7.15.3 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Major Product Offerings
7.15.4 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in Global Market (2018-2023)
7.15.5 D3 Bio Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer